Search

Author/Creator Louie, Thomas J

1. 221. Assessment and Proposed Revision of Clinical Trial Clostridioides difficile Infection Clinical Response and Outcomes Definitions. (15th December 2022)

Authors:
Gonzales-Luna, Anne J; Skinner, Andrew M; Alonso, Carolyn D; Cornely, Oliver A; Garey, Kevin W; Gerding, Dale N; Johnson, Stuart; Kahn, Stacy A; Kelly, Ciaran P; Kelly, Colleen R; Kociolek, Larry K; Kuijper, Ed J; Kuijper, Ed J; Louie, Thomas J; Riley, Thomas V; Sandora, Thomas J; Vehreschild, Ma...
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 404. Surveillance of Clostridioides difficile Burden in Hospitals Through Wastewater Analysis. (15th December 2022)

Authors:
Au, Emily; Waddell, Barbara Jean M; Acosta, Nicole; Du, Kristine; Chavarriaga, Maria Bautista; McCalder, Janine; Doorn, Jennifer Van; Low, Kashtin; Lu, Xuewen; Chekouo, Thierry; Dai, Xiaotian; Cabaj, Jason; Hrudey, Steve; Bhatnagar, Srijak; Ruecker, Norma J; Achari, Gopal; Cathryn Ryan, M; Clark,...
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 634. Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides difficile Infection (CDI) Compared to Placebo, Regardless of Risk Factors for Recurrence. (4th December 2021)

Authors:
Cohen, Stuart H; Louie, Thomas J; Sims, Matthew; Pullman, John; Wang, Elaine E; Wang, Elaine E; Wu, Henry; McGovern, Barbara; Brady, Kelly; von Moltke, Lisa
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S420
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 639. Time to Recurrence of Clostridioides difficile Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic. (4th December 2021)

Authors:
Louie, Thomas J; Sims, Matthew; Nathan, Richard; O'Marro, Steven; Kumar, Princy N; Wang, Elaine E; Wang, Elaine E; Stevens, Robert; Brady, Kelly; McGovern, Barbara; von Moltke, Lisa
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S422
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 639. Time to Recurrence of Clostridioides difficile Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic. (4th December 2021)

Authors:
Louie, Thomas J; Sims, Matthew; Nathan, Richard; O'Marro, Steven; Kumar, Princy N; Wang, Elaine E; Wang, Elaine E; Stevens, Robert; Brady, Kelly; McGovern, Barbara; von Moltke, Lisa
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S422
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection. (15th December 2022)

Authors:
Okhuysen, Pablo C; Ramesh, Mayur; Garey, Kevin W; Louie, Thomas J; Cisneros, Julian Torre; Stychneuskaya, Alena; Kiknadze, Nino; LI, Jianling; Duperchy, Esther; Wilcox, Professor Mark H; Montoya, Jose G; Styles, Lori; Clow, Fong; James, Danelle; Dubberke, Erik R; De Oliveira, Claudia M; Van Steen...
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Issue 3 (March 2019)

Authors:
Gerding, Dale N; Cornely, Oliver A; Grill, Simon; Kracker, Hilke; Marrast, Anne Claire; Nord, Carl Erik; Talbot, George H; Buitrago, Martha; Gheorghe Diaconescu, Iulian; Murta de Oliveira, Claudia; Preotescu, Liliana; Pullman, John; Louie, Thomas J; Wilcox, Mark H
Journal:
Lancet infectious diseases
Issue:
Volume 19:Issue 3(2019)
Page Start:
265
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD). (31st December 2020)

Authors:
Ducher, Annie; Vehreschild, Maria J G T; Vehreschild, Maria J G T; Louie, Thomas J; Cornely, Oliver A; Féger, Céline; Dane, Aaron; Dane, Aaron; Varastet, Marina; de Gunzburg, Jean; Andremont, Antoine; Mentré, France
Journal:
Open forum infectious diseases
Issue:
Volume 7:Number 1(2020) Supplement
Page Start:
S845
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. LB15. SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics. (4th December 2021)

Authors:
Straub, Timothy J; Diao, Liyang; Ford, Christopher; Sims, Matthew; Louie, Thomas J; Berenson, Charles; Kraft, Colleen S; Cohen, Stuart H; Cohen, Stuart H; Paskovaty, Alla; Lombardo, Mary-Jane; McGovern, Barbara; von Moltke, Lisa; Henn, Matt
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S812
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗